AccScience Publishing / Bladder / Online First / DOI: 10.14440/bladder.2025.0001
Submit to Bladder
Cite this article
1
Download
71
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW

Minimally invasive surgical treatments for male lower urinary tract symptoms/benign prostatic enlargement: A review on sexual function outcomes

Eric Chung1,2,3*
Show Less
1 Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland 4102, Australia
2 AndroUrology Centre, Brisbane, Queensland 4000, Australia
3 Department of Urology, Macquarie University Hospital, Sydney, New South Wales 2113, Australia
Bladder, e21200051 https://doi.org/10.14440/bladder.2025.0001
Submitted: 2 January 2025 | Revised: 7 March 2025 | Accepted: 25 April 2025 | Published: 11 June 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Background: Male lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) represent a common urological condition, especially in older males. Literature supports a strong association between male LUTS/BPE and sexual dysfunction. While transurethral resection of the prostate is often considered the standard for male LUTS/BPE surgical treatment, it causes complications across various male sexual domains, such as erectile dysfunction and ejaculatory disorders. In recent years, there have been considerable advances in minimally invasive surgical treatments (MISTs) for male LUTS/BPE. Published literature has shown that MISTs can improve various parameters of voiding domains while minimizing adverse sexual effects. Objective: This article provides an overview of the present understanding of the association between male LUTS/BPE and sexual dysfunction, and the present commercially available MISTs, with a specific focus on sexual function outcomes. Conclusion: Present MISTs for male LUTS/BPE have demonstrated considerable improvements in various urinary parameters while minimizing adverse effects across different sexual function domains.

Keywords
Benign prostatic hyperplasia
Lower urinary tract symptoms
Minimally invasive surgery
Sexual function
Erectile dysfunction
Ejaculatory function
Clinical outcomes
Funding
None.
Conflict of interest
The author declares no conflict of interest.
References
  1. GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the global burden of disease study 2019. Lancet Healthy Longev. 2022;3(11):e754-e776. doi: 10.1016/S2666-7568(22)00213-6

 

  1. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637-649. doi: 10.1016/j.eururo.2003.08.015

 

  1. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: A survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-1354. doi: 10.1111/j.1464-410X.2005.05831.x

 

  1. Zhao H, Kim HH. The complex relationship between lower urinary tract symptoms and sexual health. Curr Urol Rep. 2019;20(10):58. doi: 10.1007/s11934-019-0930-4

 

  1. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part 1 - initial work-up and medical management. J Urol. 2021;206(4):806-817. doi: 10.1097/JU.0000000000002183

 

  1. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140. doi: 10.1016/j.eururo.2013.03.004

 

  1. Strope SA. Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care. Curr Opin Urol. 2018;28(3):262-266. doi: 10.1097/MOU.0000000000000504

 

  1. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guidelines part II- Surgical evaluation and treatment. J Urol. 2021;206(4):818-826. doi: 10.1097/JU.0000000000002184

 

  1. Chua ME, Mendoza J, See M 4th, et al. A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms. Can Urol Assoc J. 2015;9(7-8):E463-E470. doi: 10.5489/cuaj.2424

 

  1. Morton A, Williams M, Perera M, et al. Management of benign prostatic hyperplasia in the 21st century: Temporal trends in Australian population-based data. BJU Int. 2020;126(Suppl 1):18-26. doi: 10.1111/bju.15098

 

  1. La Vignera S, Aversa A, Cannarella R, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: Consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021;22(2): 179-189. doi: 10.1080/14656566.2020.1817382

 

  1. Manfredi C, Garcia-Gomez B, Arcaniolo D, et al. Impact of surgery for benign prostatic hyperplasia on sexual function: A systematic review and meta-analysis of erectile function and ejaculatory function. Eur Urol Focus. 2022;8(6):1711-1732. doi: 10.1016/j.euf.2022.06.007

 

  1. Franco JVA, Jung JH, Imamura M, et al. Minimally invasive treatments for benign prostatic hyperplasia: A cochrane network meta-analysis. BJU Int. 2022;130(2):142-156. doi: 10.1111/bju.15653

 

  1. Ng BHS, Chung E. A state-of-art review on the preservation of sexual function among various minimally invasive surgical treatments for benign prostatic hyperplasia: Impact on erectile and ejaculatory domains. Investig Clin Urol. 2021;62(2): 148-158. doi: 10.4111/icu.20200392

 

  1. Enikeev D, Misrai V, Rijo E, et al. EAU, AUA and NICE guidelines on surgical and minimally invasive treatment of benign prostate hyperplasia: A critical appraisal of the guidelines using the AGREE-II tool. Urol Int. 2022;106(1):1-10. doi: 10.1159/000517675

 

  1. Dixon C, Cedano ER, Pacik D, et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042-1047. doi: 10.1016/j.urology.2015.05.046

 

  1. Westwood J, Geraghty R, Jones J, Rai P, Somani BK. Rezum: A new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10(11):327-333. doi: 10.1177/1756287218793084

 

  1. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529-1538. doi: 10.1016/j.juro.2015.10.181

 

  1. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: Convective radiofrequency thermal therapy for Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111:1-9. doi: 10.1016/j.urology.2017.10.023

 

  1. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171-179. doi: 10.1016/j.urology.2018.12.041

 

  1. McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018;15(12):1728-1738. doi: 10.1016/j.jsxm.2018.10.006

 

  1. Spinos T, Katafigiotis I, Leotsakos I, et al. Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: A systematic review of the literature. World J Urol. 2023;41(2):413-420. doi: 10.1007/s00345-022-04258-y

 

  1. Babar M, Loloi J, Tang K, Syed U, Ciatto M. Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review. Low Urin Tract Symptoms. 2022;14(3):140-154. doi: 10.1111/luts.12435

 

  1. Yang J, Wu W, Amier YT, et al. Efficacy and safety of water vapor thermal therapy in the treatment of benign prostate hyperplasia: A systematic review and single-arm meta-analysis. BMC Urol. 2023;23(1):72. doi: 10.1186/s12894-023-01237-2

 

  1. Roehrborn CG, Chin PT, Woo HH. The Urolift implant: Mechanism behind rapid and durable relief from prostatic obstruction. Prostate Cancer Prostatic Dis. 2022;25(1):79-85. doi: 10.1038/s41391-021-00434-0

 

  1. McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: Surgical technique and multinational experience. Eur Urol. 2013;64(2):292-299. doi: 10.1016/j.eururo.2013.01.008

 

  1. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802-8813.

 

  1. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119(5):767-775. doi: 10.1111/bju.13714

 

  1. Jung JH, Reddy B, McCutcheon KA, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019;5(5):CD012832. doi: 10.1002/14651858.CD012832.pub2

 

  1. Miller LE, Chughtai B, Dornbier RA, McVary KT. Surgical reintervention rate after prostatic urethral lift: Systematic review and meta-analysis involving over 2,000 patients. J Urol. 2020;204(5):1019-1026. doi: 10.1097/JU.0000000000001132

 

  1. Xiang P, Wang M, Guan D, et al. A systematic review and meta-analysis of prostatic urethral lift for male lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol Open Sci. 2020;19:3-15. doi: 10.1016/j.euros.2020.05.001

 

  1. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. Int Urol Nephrol. 2020;52(6):999-1008. doi: 10.1007/s11255-020-02408

 

  1. Jing J, Wu Y, Du M, et al. Urethral lift as a safe and effective procedure for prostatic hyplasia population: A systematic review and meta-analysis. Front Surg. 2020;7:598728. doi: 10.3389/fsurg.2020.598728

 

  1. Balakrishnan D, Jones P, Somani BK. iTIND: The second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia. Ther Adv Urol. 2020;12. doi: 10.1177/1756287220934355

 

  1. Fiori C, De Cillis S, Volpi G, et al. iTIND for BPH: Technique and procedural outcomes: A narrative review of current literature. Turk J Urol. 2021;47(6):470-481. doi: 10.5152/tud.2021.21145

 

  1. Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): A novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): Feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116(2):278-287. doi: 10.1111/bju.12982

 

  1. Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2021;24:349-357. doi: 10.1038/s41391-020-00281-5

 

  1. Chughtai B, Elterman D, Shore N, et al. The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A multicenter, randomized, controlled trial. Urology. 2021;153(20):270-276. doi: 10.1016/j.urology.2020.12.022

 

  1. Kadner G, Valerio M, Giannakis I, et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020;38:(12):3235-3244. doi: 10.1007/s00345-020-03140-z

 

  1. Porpiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: Results of a prospective, multicentre study at 1 year of follow-up. BJU Int. 2019;123(6):1061-1069. doi: 10.1111/bju.14608

 

  1. Pisco JM, Bilhim T, Pinheiro LC, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: Results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115-1122. doi: 10.1016/j.jvir.2016.04.001

 

  1. Salem R, Hairston J, Hohlastos E, et al. Prostate artery embolization for lower urinary tract symptoms secondary to benign prostatic hyperplasia: Results from a prospective FDA-approved investigational device exemption study. Urology. 2018;120:205-210. doi: 10.1016/j.urology.2018.07.012

 

  1. Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): Preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol. 2016;39(1):44-52. doi: 10.1007/s00270-015-1202-4

 

  1. Abt D, Schmid HP, Speakman MJ. Reasons to consider prostatic artery embolization. World J Urol. 2021;39(7): 2301-2306. doi: 10.1007/s00345-021-03601-z

 

  1. Moulin B, Di Primio M, Vignaux O, Sarrazin JL, AngelopoulosG, Hakime A. Prostatic artery embolization: Challenges, tips, tricks, and perspectives. J Pers Med. 2023;13(1):87. doi: 10.3390/jpm13010087

 

  1. Carnevale FC, De Assis AM, Moreira AM. Prostatic artery embolization: Equipment, procedure, steps, and overcoming technical challenges. Tech Vasc Interv Radiol. 2020;23(3):100691.doi: 10.1016/j.tvir.2020.100691

 

  1. Sun F, Crisóstomo V, Báez-Díaz C, Sánchez FM. Prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH): Part 2, insights into the technical rationale. Cardiovasc Intervent Radiol. 2016;39(2):161-169. doi: 10.1007/s00270-015-1238-5

 

  1. Xu XJ, Li J, Huang XZ, Liu Q. An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. World J Urol. 2020;38(10):2455-2468. doi: 10.1007/s00345-019-03044-7

 

  1. Jung JH, McCutcheon KA, Borofsky M, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2022;3(3):CD012867. doi: 10.1002/14651858.CD012867.pub3

 

  1. Jiang YL, Qian LJ. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: A meta-analysis. BMC Urol. 2019;19(1):11. doi: 10.1186/s12894-019-0440-1

 

  1. Shim SR, Kanhai K, Ko YM, Kim JH. Efficacy and safety of prostatic artery embolization: Systematic review with meta-analysis and meta-regression. J Urol. 2017;197(2):465-479. doi: 10.1016/j.juro.2016.08.100

 

  1. Zumstein V, Betschart P, Vetterlein MW, et al. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. Eur Urol Focus. 2018;5(6):1091-1100. doi: 10.1016/j.euf.2018.09.005

 

  1. Chung E. Penile glans necrosis following prostatic artery embolization for benign prostatic hyperplasia: Case series and review of current literature. World J Mens Health. 2023;41(2):396-402. doi: 10.5534/wjmh.210244

 

  1. Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2017;10:29-43. doi: 10.2147/CEOR.S148195
Next article in this issue
Share
Back to top
Bladder, Electronic ISSN: 2327-2120 Print ISSN: TBA, Published by POL Scientific
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept